Article
Bevacizumab rescue therapy after pegaptanib: minimal visual acuity improvement
Primary bevacizumab (Avastin, Genentech) therapy for choroidal neovascularization (CNV) in age-related macular degeneration resulted in two to three ETDRS lines of improvement, which is similar to that with ranibizumab (Lucentis, Genentech). Bevacizumab rescue therapy administered following treatment with pegaptanib (Macugen, OSI/Eyetech, Pfizer Ophthalmics) resulted in minimal improvement, said William Freeman, MD, from the Department of Ophthalmology, Shiley Eye Center, University of California San Diego, La Jolla, CA.
Related Videos
Related Content
Published: December 19th 2024 | Updated: December 19th 2024
Study validates long-term efficacy of MicroPulse TLT for glaucoma management
